


*add B7*

**Claims :**

1. Use of a compound of general formula (I):



**Formula (I)**

wherein :

R<sup>1</sup> represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C<sub>1</sub>-6alkyl, C<sub>1</sub>-6alkoxy, arylC<sub>1</sub>-6alkoxy, -CO<sub>2</sub>R<sup>4</sup>,  
 -(CH<sub>2</sub>)<sub>n</sub>CN, -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>5</sup>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>,  
 C<sub>1</sub>-6alkanoylamino(CH<sub>2</sub>)<sub>n</sub>, or  
 C<sub>1</sub>-6alkylsulphonylamino(CH<sub>2</sub>)<sub>n</sub>;

R<sup>4</sup> represents hydrogen, C<sub>1</sub>-6alkyl or arylC<sub>1</sub>-6alkyl;

R<sup>5</sup> and R<sup>6</sup> each independently represent hydrogen or C<sub>1</sub>-6alkyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a ring;

n represents 0, 1 or 2; and

R<sup>2</sup> and R<sup>3</sup> each independently represent hydrogen, C<sub>1</sub>-6alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring;

or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT<sub>1</sub>-like agonist is indicated.

2. Use according to claim 1 wherein the condition is migraine.


3. Use of a compound according to either claim 1 or claim 2 wherein R<sup>1</sup> represents halogen, CF<sub>3</sub>, C<sub>1</sub>-6alkoxy,

$-(CH_2)_nCN$ ,  $-(CH_2)_nCONR^5R^6$ ,  $-(CH_2)_nSO_2RN^5R^6$  or  $C_{1-6}$ alkanoylamino, and  $R^5$  and  $R^6$  are as hereinbefore defined.

4. Use of a compound according to claim 3 wherein  $R^1$  is a group  $-(CH_2)_nCONR^5R^6$ , wherein  $n$  is zero and  $R^5$  and  $R^6$  each independently represent hydrogen, methyl or ethyl.

5. Use of a compound according to any of claims 1 to 3 wherein  $R^2$  and  $R^3$  each independently represent hydrogen, methyl or ethyl.

6. A compound of formula (IA) :



Formula (IA)

wherein  $R^1$  is as hereinbefore defined with the proviso that  $R^1$  is not hydrogen, hydroxy, methoxy or benzyloxy, or a salt thereof.

7. A compound of formula (I) selected from :

- 3-Amino-6-cyano-1,2,3,4-tetrahydrocarbazole;
- (+)-3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;
- (-)-3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-bromo-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-methyl-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-ethoxycarbonyl-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-(N-methyl carboxamido)-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-cyanomethyl-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-(N-methylsulphonamidomethyl)-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-chloro-1,2,3,4-tetrahydrocarbazole;
- 3-amino-6-trifluoromethyl-1,2,3,4-tetrahydrocarbazole;


3-amino-6-n-butyloxy-1,2,3,4-tetrahydrocarbazole;  
3-amino-6-sulphonamido-1,2,3,4-tetrahydrocarbazole;  
3-amino-6-nitro-1,2,3,4-tetrahydrocarbazole;  
3-amino-6-(N,N-dimethylcarboxamido)-1,2,3,4-tetrahydro-  
5 carbazole;  
3-amino-6-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro-  
carbazole;  
3-amino-6-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydro-  
carbazole;  
10 3-amino-6-(N,N-diethylcarboxamido)-1,2,3,4-tetrahydro-  
carbazole;  
3-Amino-6-(acetamido)-1,2,3,4-tetrahydrocarbazole;  
3-amino-6-methanesulphonamido-1,2,3,4-tetrahydrocarbazole;  
3-amino-6-carboxamidomethyl-1,2,3,4-tetrahydrocarbazole;  
15 3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
3-ethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
3-n-propylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
3-i-propylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
3-dimethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
20 3-benzylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
3-pyrrolidinyl-6-carboxamido-1,2,3,4-tetrahydrocarbazole;  
3-(N-(methyl)ethylamino)-6-carboxamido-1,2,3,4-tetrahydro-  
carbazole; and  
3-amino-6-(2-carboxamidoethyl)-1,2,3,4-tetrahydrocarbazole;  
25 or a salt thereof.

8. A method of treatment of a condition wherein a  
5-HT<sub>1</sub>-like agonist is indicated, which comprises administering  
to a subject in need thereof an effective amount of a compound  
30 of formula (I) as hereinbefore defined or a physiologically  
acceptable salt thereof.

9. A process for the preparation of a compound of  
formula (I) as defined in claim 6 or claim 7 which comprises :

35


A) Reaction of a compound of formula (II) :



5

Formula (II)

(wherein  $R^1$  is as hereinbefore defined) or an acid addition salt thereof with a compound of formula (III) :




10

Formula (III)

(wherein  $R^2$  and  $R^3$  are as hereinbefore defined) or an N-protected derivative thereof; or

15

B) Reaction of a compound of formula (IV) :




20

Formula (IV)

(wherein  $R^1$  is as defined for formula (I) and  $Z$  is a leaving group) with a compound of formula  $HNR^2R^3$ ;

25

C) Reacting a compound of formula (V) :



Formula (V)

5 with an acylating or sulphonylating agent;

D) Conversion of one compound of formula (I) into another compound of formula (I) eg.

10 (i) to prepare a compound of formula (I) wherein  $\text{R}^1$  represents  $-(\text{CH}_2)_n\text{CONH}_2$  or  $\text{CO}_2\text{R}^4$ , hydrolysis of a compound of formula (I) wherein  $\text{R}^1$  represents  $-(\text{CH}_2)_n\text{CN}$ , or an N-protected derivative thereof;

15 (ii) to prepare a compound of formula (I) wherein  $\text{R}^1$  represents  $-\text{CONR}^5\text{R}^6$ , amination of a compound of formula (I) wherein  $\text{R}^1$  represents  $-\text{CO}_2\text{H}$ , or an N-protected derivative thereof; or

20 (iii) to prepare a compound of formula (I) wherein one of  $\text{R}^2$  and  $\text{R}^3$  is hydrogen and the other is  $\text{C}_{1-6}$ alkyl, alkylation of a compound (I) in which  $\text{R}^2$  and  $\text{R}^3$  are both hydrogen;

25 (iv) to prepare a compound of formula (I) wherein  $\text{R}^1$  represents hydroxy, cleavage of a compound wherein  $\text{R}^1$  represents alkoxy or aralkoxy;

30 followed if necessary by deprotection of any protected nitrogen atoms and if desired by salt formation.

26 APRIL 19

- 43 -

10. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 6 or claim 7 or a physiologically acceptable salt thereof and a physiologically acceptable carrier.

5

Add A1